News

Treatment with Trikafta rapidly eases symptoms of chronic nose and sinus inflammation in people with cystic fibrosis (CF), according to a new study — in which researchers noted that 30-60% of CF patients report symptoms of sinus disease. …

Treatment with Trikafta improves lung function in people with cystic fibrosis (CF) who are not eligible for treatment with other CFTR modulators, according to interim data from an observational study. Results were shared at this year’s North American Cystic Fibrosis Conference (NACFC) in the presentation, “…

Clinicians who are caring for people with cystic fibrosis (CF) should talk to their patients about pregnancy and family planning “early and often,” according to researchers. In a presentation at the 2021 North American Cystic Fibrosis Conference (NACFC), Kristina Montemayor, MD, an assistant professor at Johns Hopkins University, also…

Six months of treatment with Trikafta does not substantially alter digestive symptoms in people with cystic fibrosis (CF), new research shows. “We speculate that [Trikafta], while it may lead to improvement in lung function, may have little or very delayed impact on gastrointestinal symptoms in people with CF,” Sarah…

A retrospective study by the National Institutes of Health (NIH) suggests that healthcare costs for those with rare diseases have been underestimated, possibly being three to five times higher than for those without rare diseases. This study provides evidence of the potential effect rare diseases may have on public health…

For children with cystic fibrosis (CF), newborn screening is associated with markedly improved real-world outcomes, including earlier diagnosis, greater weight and height gains, and fewer bacterial infections, new research demonstrates. In fact, infants are now diagnosed with the genetic disease at a median of 0 months…

The Cystic Fibrosis Foundation (CFF) is partnering with Pioneering Medicines, an initiative of Flagship Pioneering, to support the development of various types of gene therapy for cystic fibrosis (CF). The foundation is ready to invest up to $110 million to move therapy candidates into clinical testing, starting with an…

People with cystic fibrosis (CF) who start on the triple therapy Trikafta may be at greater risk of problems associated with excessive weight or obesity, such as metabolic syndrome — a group of disorders known to raise a risk of heart, liver, and kidney disease. “With the approval…

Treatment with Orkambi (lumacaftor/ivacaftor) and/or Symdeko (tezacaftor/ivacaftor) may lessen liver damage in children and adolescents with cystic fibrosis (CF) who have liver involvement, new data indicate. “We detected improvements in validated noninvasive biomarkers of liver fibrosis [scarring] and cirrhosis in children and adolescents treated with” these therapies, the…

Treatment with Trikafta can help people with cystic fibrosis (CF) to put on weight, according to new data from a small clinical trial. These findings indicate that traditional guidelines for CF nutrition — which urge a…